Advertisement
Canada markets open in 2 hours 23 minutes
  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CAD/USD

    0.7325
    +0.0002 (+0.03%)
     
  • CRUDE OIL

    84.04
    +0.47 (+0.56%)
     
  • Bitcoin CAD

    87,580.23
    +860.15 (+0.99%)
     
  • CMC Crypto 200

    1,384.59
    -11.95 (-0.86%)
     
  • GOLD FUTURES

    2,360.10
    +17.60 (+0.75%)
     
  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • NASDAQ futures

    17,721.25
    +153.75 (+0.88%)
     
  • VOLATILITY

    15.65
    +0.28 (+1.82%)
     
  • FTSE

    8,112.72
    +33.86 (+0.42%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6822
    +0.0001 (+0.01%)
     

Dr Reddy's Laboratories isolates all its data centre services following cyber attack

The pharmaceutical company Dr Reddy's Laboratories Ltd. (File Photo)
The pharmaceutical company Dr Reddy's Laboratories Ltd. (File Photo)

Hyderabad (Telangana) [India], October 23 (ANI): The pharmaceutical company Dr Reddy's Laboratories Ltd has isolated all its data centres following a cyber attack on Thursday.

According to the statement, the company has isolated all data centre services as a 'preventive action'.

Speaking about the incident Mukesh Rathi, ClO, Dr Reddy's Laboratories said, "We are anticipating all services to be up within 24 hours and we do not foresee any major impact on our operations due to this incident."

Recently, the expert committee of Drugs Controller General of India (DCGI) had recommended granting permission to Dr Reddy's Laboratories for conducting phase 2 clinical trials of Russian COVID-19 vaccine candidate, Sputnik V, in India.

ADVERTISEMENT

According to the government official, Dr Reddy's Lab has stated that in phase 2 clinical trial--"would include 100 subjects and for phase 3, it would take 1400 subjects."

"Once the pharma company would submit the safety and immunogenicity data of phase 2, it would be analysed by the expert panel and then they can proceed for the phase 3 trial," the official added. (ANI)